JNJ-90014496: A phase 1 trial of JNJ-90014496 in people with relapsed or refractory B-cell non-Hodgkin lymphoma

This trial is testing the medication JNJ-90014496 in adults with B-cell non-Hodgkin lymphoma (NHL) who have disease which has come back after (relapsed) or not responded to (refractory) treatment.

You can share the following isrctn.com Identifier with your medical team so they can find out more about the trial: ISRCTN15038320

Trial aim and background  

The aim of this trial is to find out if the treatment JNJ-90014496 can be used in future studies for the treatment of B-cell NHL. It aims to see what side effects there are, how long the medication stays in the body, and how the body responds to it.

JNJ-90014496 is a bispecific CAR-T therapy which uses a patient’s own T-cells to attack the cancer cells

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter 

People over 18 with B-cell NHL who have relapsed or refractory disease after two previous treatments may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • University College London Hospitals NHS Foundation Trust, London
  • The Christie NHS Foundation Trust, Manchester

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.isrctn.com/ISRCTN15038320

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.